Low-dose resveratrol supplementation on heart rate variability in hypertensive volunteers: a controlled double-blind trial

Silva-e-Oliveira, Julia; Ferrão, Diêne; Damasceno, Dênis; Furtado, Fabianne

doi:10.5935/MedicalExpress.2016.06.06

Brasil

Español English

RAPID COMMUNICATION • MedicalExpress (São Paulo, online) 3 (6) • Nov-Dec 2016 • https://doi.org/10.5935/MedicalExpress.2016.06.06 copy

Low-dose resveratrol supplementation on heart rate variability in hypertensive volunteers: a controlled double-blind trial

SUPLEMENTAÇÃO DE BAIXA DOSE DE RESVERATROL NA VARIABILIDADE DA FREQUÊNCIA CARDÍACA EM HIPERTENSOS: ENSAIO CLINICO CONTROLADO E DUPLO CEGO

Authorship SCIMAGO INSTITUTIONS RANKINGS

OBJECTIVE:

Hypertension decreases the heart rate variability (HRV). Resveratrol, a phenolic compound found in grapes and their products, has been explored for its potential to treat hypertension. We evaluated the effects of low-dose resveratrol on HRV in hypertensive volunteers.

METHOD:

Twenty-one hypertensive volunteers of both sexes were supplemented with resveratrol (n = 11) or placebo (n = 10) for 30 days. HRV parameters were measured before and during a standardized treadmill exercise. One resveratrol- and 3 placebo-treated patients were lost to follow-up.

RESULTS:

There were no anthropometric differences between resveratrol (n = 10) and placebo (n = 7) other than a difference in body mass index. The measured HRV parameters did not differ between resveratrol and placebo, or between control and treadmill exercise.

CONCLUSION:

Low-dose resveratrol did not alter HRV in hypertensive patients.

KEYWORDS:
Grape seed extract; Hypertension; Autonomic nervous system

	Resveratrol group (n=10)	Placebo group (n=7)	p
Age (years)	54.4±9.0	55.7±9.0	0.77
Male/Female	6/4	0/7	0.64
Systolic Blood pressure (mm Hg)	136.0±11.7	140.0 ± 22.4	0.64
Diastolic Blood pressure (mm Hg)	90.0±12.7	95.7±12.7	0.37
Years from diagnosis of hypertension	10.4±10.1	10.6±7.6	0.97
Body Mass Index	35.2±5.2	29.3±3.5	0.01
Smokers	none	none	-
Alcoholic drink consumers	70.4%	70.0	0.55
Exercising activity (less than 30 min/day)	85.7%	90.0%	>0.99

		Placebo group	Resveratrol group	Interaction	Time	Group
At rest	TIME DOMAIN
	Mean RR (msec)
	Pre	832.01 ±101.98	774.430 ±186.73	0.31	0.14	0.84
	Post	854.18 ±142.06	888.19 ±136.45
	SDNN
	Pre	36.7 ±20.12	40.97 ±10.03	0.88	0.54	0.45
	Post	39.62 ±23.02	45.73 ±21.12
	RMSSD
	Pre	20.28 ±16.71	28.04 ±16.55	0.98	0.90	0.15
	Post	20.87 ±7.49	28.77 ±15.64
	PNN50
	Pre	6.74 ±13.05	4.22 ±6.94	0.16	0.83	0.65
	Post	2.92 ±2.64	9.38 ±15.01
	Triangular Index
	Pre	6.97 ±3.71	8.42 ±3.08	0.66	0.30	0.52
	Post	8.80 ±3.42	8.80 ±3.42
	FREQUENCY DOMAIN
	VLS (ms²)
	Pre	530.48 ±520.07	781.9 ±404.19	0.69	0.47	0.27
	Post	655 ±636.34	1210 ±1750.04
	HF (ms²)
	Pre	248.42 ±357.29	218.89 ±272.71	0.34	0.85	0.53
	Post	152.42 ±98.24	360.20 ±555.85
	LF (ms²)
	Pre	347.57 ±341.11	346.3 ±403.96	0.98	0.91	0.97
	Post	336.85 ±264.38	329.4 ±383.49
	LF/HF
	Pre	3.42 ±3.48	1.82 ±1.68	0.59	0.37	0.08
	Post	2.48 ±1.1	1.58 ±0.8
Stress (on the treadmill)	TIME DOMAIN
	Mean RR (msec)
	Pre	586.58 ±156.90	552.88 ±77.45	0.29	0.30	0.81
	Post	540.95 ±64.95	553.51 ±93.99
	SDNN
	Pre	24.01 ±20.49	30.73 ±12.08	0.45	0.63	0.51
	Post	25.37 ±11.13	24.86 ±9.37
	RMSSD
	Pre	11.10 ±13.53	17.59 ±16.65	0.47	0.29	0.52
	Post	9.44 ±10.01	8.90 ±11.80
	PNN50
	Pre	0.87 ±2.09	1.84 ±3.71	0.59	0.63	0.65
	Post	0.92 ±1.82	0.82 ±2.5
	Triangular Index
	Pre	4.12 ±1.79	4.93 ±2.03	0.95	0.54	0.21
	Post	4.42 ±0.77	5.29 ±1.63
	FREQUENCY DOMAIN
	VLS (ms²)
	Pre	591.71 ±1165.02	302.80 ±193.56	0.52	0.40	0.39
	Post	292.14 ±237.23	259.70 ±127.7
	HF (ms²)
	Pre	80.71 ±199.61	78.14 ±162.79	0.91	0.41	0.95
	Post	32 ±69.81	40.1 ±116.28
	LF (ms²)
	Pre	114 ±277.54	107 ±132.49	0.85	0.41	0.76
	Post	74.42 ±161.78	45.6 ±102.57
	LF/HF
	Pre	2.46 ±1.37	3.37 ±2.50	0.94	0.24	0.44
	Post	3.07 ±1.98	4.06 ±3.65

		Placebo group	Resveratrol group	Interaction^* * ANOVA repeated measurements; data described as mean ± standard deviation; ApEn: approximate entropy; SamEn: sample entropy.	Time^* * ANOVA repeated measurements; data described as mean ± standard deviation; ApEn: approximate entropy; SamEn: sample entropy.	Group^* * ANOVA repeated measurements; data described as mean ± standard deviation; ApEn: approximate entropy; SamEn: sample entropy.
At rest	SD1
	Pre	15.15 ± 10.84	19.75 ± 11.73	0.89	0.97	0.16
	Post	14.75 ± 5.29	20.36 ± 11.07
	SD2
	Pre	49.2 ± 27.1	53.8 ± 11.91	0.89	0.50	0.53
	Post	53.85 ± 32.47	60.82 ± 28.42
	ApEn
	Pre	1.15 ± 0.43	1.03 ± 0.37	0.82	0.32	0.13
	Post	1.32 ± 0.18	1.13 ± 0.3
	SamEn
	Pre	1.19 ± 0.56	1.02 ± 0.5	0.86	0.27	0.19
	Post	1.41 ± 0.22	1.19 ± 0.45
Stress (on the treadmill)	SD1
	Pre	7.85 ± 9.58	12.44 ± 11.78	0.47	0.29	0.52
	Post	6.67 ± 7.05	6.3 ± 8.34
	SD2
	Pre	32.74 ± 27.55	40.65 ± 15.41	0.49	0.73	0.56
	Post	34.94 ± 14.79	34.08 ± 11.87
	ApEn
	Pre	0.72 ± 0.35	0.67 ± 0.28	0.44	0.77	0.77
	Post	0.66 ± 0.28	0.78 ± 0.33
	SamEn
	Pre	0.66 ± 0.40	0.59 ± 0.31	0.33	0.74	0.69
	Post	0.58 ± 0.33	0.75 ± 0.34

Mavera Edições Técnicas e Científicas Ltda Rua Professor Filadelfo Azevedo, 220, Cep: 04508-010, tel: (11) 3051 3043 - São Paulo - SP - Brazil
E-mail: medicalexpress@me.net.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] E-mail: fabianne.furtado@ifsudestemg.edu.br